NCT01711632已完成2 期
A Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 5
- 主要终点
- Efficacy of Vemurafenib
研究概览
简要总结
The purpose of this study is to find out what effects, good and/or bad, treatment with vemurafenib (also known as Zelboraf™) has on the patient and on leukemia. Specifically, the researchers want to know how well vemurafenib eliminates leukemia from the blood.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 18 years of age
- •Histologically confirmed classical HCL with one of the following:
- •Intolerance to purine analogs or considered to be poor candidates for purine analog-based therapy
- •Failure to achieve any response (CR or PR) to the initial purine analog-based therapy
- •Relapse ≤ 2 years of purine analog-based therapy
- •≥ 2 relapses Histologic confirmation of diagnosis will be performed at MSKCC or a participating site.
- •Patients who meet the standard treatment initiation criteria, as defined by ANC ≤1.0, Hgb ≤ 10.0 or PLT ≤100K
- •ECOG performance status of 0-2
- •Acceptable pre-study organ function during screening as defined as: Total bilirubin ≤ 1.5 times the upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x ULN, and serum creatinine ≤ 1.5x ULN
- •Electrocardiogram (ECG) without evidence of clinically significant ventricular arrhythmias or ischemia as determined by the investigator and a rate-corrected QT interval (QTc, Bazett's formula) of < 480 msec.
- •For women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for 6 months after discontinuation of vemurafenib
- •For men with female partners of childbearing potential, agreement to use a latex condom and to advise their female partner to use an additional method of contraception during the study and for 6 months after discontinuation of vemurafenib
- •Negative serum pregnancy test within 7 days of commencement of treatment in premenopausal women.
- •Agreement not to donate blood or blood products during the study and for at least 6 months after discontinuation of vemurafenib; for male partners, agreement not to donate sperm during the study and for at least 6 months after discontinuation of vemurafenib
- •Ability to understand and willingness to sign a written informed consent document.
- •Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
排除标准
- •Pregnant or breast-feeding
- •Have had chemotherapy (including purine analogs, rituximab, and other investigational agents) within six weeks prior to entering the study
- •Major surgery within 4 weeks prior to entering the study
- •Invasive malignancy within the past 2 years prior to first study drug administration, except for adequately treated (with curative intent) basal or squamous cell carcinoma, melanoma, in situ carcinoma of the cervix, in situ ductal adenocarcinoma of the breast, in situ prostate cancer, or limited stage bladder cancer or other cancers from which the patient has been disease-free for at least 2 years
- •Refractory nausea or vomiting, malabsorption, external biliary shunt, or history of any type of gastrointestinal surgery that would preclude adequate absorption of study drug
- •Prior treatment with MEK or BRAF inhibitors
- •Active HIV, hepatitis B and hepatitis C
- •Patients with HCL variant (as defined by absence of expression of CD25 or absence of BRAF V600E mutation)
研究组 & 干预措施
Vemurafenib
Experimental
Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days).
干预措施: Vemurafenib (Drug)
结局指标
主要结局
Efficacy of Vemurafenib
时间窗: 3 months
as assessed by overall response rates after three months of treatment in patients with relapsed or refractory HCL. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
次要结局
- Toxicity (Safety and Tolerability)(2 years)
- To Assess the Pharmacodynamics Change From Baseline(2 years)
- Evaluate Biomarkers of Resistance(2 years)
研究者
研究点 (5)
Loading locations...
相似试验
终止
2 期
Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K MutationMelanomaNCT01474551Memorial Sloan Kettering Cancer Center2
进行中（未招募）
2 期
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell LeukemiaHairy Cell LeukemiaLeukemia, Hairy CellLeukemiaNCT03410875Memorial Sloan Kettering Cancer Center30
已完成
1 期
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced CancerAdvanced CancerSolid TumorNCT01596140M.D. Anderson Cancer Center27
已完成
早期 1 期
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot StudyThyroid CarcinomaNCT02145143Memorial Sloan Kettering Cancer Center12
进行中（未招募）
2 期
Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive CraniopharyngiomaBRAF V600E Mutation PresentPapillary CraniopharyngiomaNCT03224767Alliance for Clinical Trials in Oncology24